RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE

The invention relates to an improved filovirus vaccine containing a recombinant modified vaccinia virus Ankara (MVA-based) vaccine against filovirus infection and related products, methods and uses. In particular, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors containing at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. In particular, the invention relates to a recombinant MVA containing an Ebola virus glycoprotein and a 40 virion protein. The invention is also related to products, methods, and uses thereof, as well as to prime/boost regimens of MVA and genetically engineered (recombinant) FPV, for example, suitable for eliciting a protective immune response in a subject.